AUTLAutolus Therapeutics plcHealthcare · Biotechnologyas of 2026-09-16
Horizon

Issued 2026-09-16 at $1.87 · now $1.87 (2026-09-16, +0.0% since)

Based on its own history, a month from the 2026-09-16 close, AUTL has typically landed between $1.28 and $2.62 — a range of −31.3% to +40.0% from the issuance price $1.87.

Range of outcomes in historically similar periods — not a price prediction. Ranges are scored publicly on /methodology.
  • Actual close
  • Typical path (median)
  • Middle 50% of outcomes
  • 90% range

2,048 overlapping 1 month windows · 2018-06-222026-08-17 · basis climatology · forecast (batch). Probability up 53.9% (90% CI 51.756.1%, ≈1,408 obs).

The cone is anchored at the 2026-09-16 issuance close ($1.87) — the price the forecast resolves against on 2026-10-15, not the latest close. The drawn path shape is illustrative (bands widen with √t); every labeled number is real — the anchor, the scored batch p90/IQR endpoints, and the typical move.

Where AUTL has typically landed a month from the 2026-09-16 close of $1.87 — the range is history, not a prediction.

$1.28worst · -31.3%$2.62best · +40.0%
  • now $1.87 (+0.0%)
  • typicalThe typical outcome — half of similar past periods did better and half did worse (not an average, so a few wild periods don't skew it). $1.81 (-3.1%)
  • middle 50%The central range of outcomes — half of similar past periods landed inside it, a quarter finished above, a quarter below. $1.55$2.07
  • 90% rangeA nine-in-ten range — in about nine of every ten similar past periods the outcome stayed within these bounds. $1.28$2.62
Actual 1-month windows behind the coneiEvery overlapping 1-month window in this security's own price history was ranked by realized return; shown are the 3 worst and 3 best of 2,048 windows spanning 2018-06-22 to 2026-09-16. Not cherry-picked — these are the extremes of the full sample. Max drop / max rise are the deepest and highest points reached within each window. See /methodology.
StartReturnMax dropMax rise
3 worst
2020-02-18−58.9%−58.9%+3.2%
2020-02-21−57.7%−59.9%+0.0%
2020-02-20−57.4%−60.2%+0.0%
3 best
2020-03-23+123.5%+0.0%+123.5%
2020-03-24+122.1%+0.0%+122.1%
2020-03-18+121.0%+0.0%+121.0%

2,048 overlapping windows · 2018-06-222026-09-16 · not cherry-picked

Seasonality · by month iHow this security has tended to do in each calendar month historically — a frequency, never a prediction.

iFor each calendar month, the share of years this security closed higher than the month before, and the average month-over-month return, over ~9 years of its own price history. Cells are shaded by average return. This is historical frequency, not a prediction — no month is a signal.
Jan
13%
−14.6%
n=8
Feb
25%
−4.8%
n=8
Mar
38%
−5.0%
n=8
Apr
38%
−4.2%
n=8
May
75%
+19.5%
n=8
Jun
50%
−1.9%
n=8
Jul
33%
+1.5%
n=9
Aug
56%
+6.2%
n=9
Sep
33%
−9.3%
n=9
Oct
25%
+1.2%
n=8
Nov
50%
+13.5%
n=8
Dec
25%
−3.4%
n=8

Up-frequency and average month-over-month return · historical frequency, not a prediction

Reported insider & political trades

Every Form 4 the people closest to this company have filed with the SEC — plotted against the share price, aggregated by month, and shown with the gap between when each trade happened and when it was disclosed. A public record, not advice.

Share price & reported tradesMonthly open-market valueReporting lag — trade date to filing date2026-092026-082026-072026-062026-052026-042026-032026-022026-012025-122025-112025-102025-092025-08$3$12026-09-02: 1 insider sale, $16K — Piccina Cintia2026-09: 1 open-market sale, $16K↑ buys↓ salesofficer Piccina Cintia — Sale on 2026-09-02, filed 1 day after the trade
DatePersonRoleActionShares @ priceValueOwnership Δvs S&P 1mvs S&P 6mOwned afterFiling
2026-09-02Piccina CintiaofficerSale6,713 @ $2.34$16K−33.6% of holdingnot yet — horizon still opennot yet — horizon still open13,287Form 4 · filed 1 day after the trade

The vs-S&P columns are a labeled look-back on what the stock did after each filing, measured against the index over the same window. Descriptive history, not a claim about the person or a reason to trade.

20 award / exercise / gift records — not counted as purchases

Awards, option exercises, gifts and tax-withholding disposals are shown separately and never counted as open-market purchases or sales — they carry no conviction information.

DatePersonRoleActionSharesOwned afterFiling
2026-09-01Piccina CintiaofficerOption exercise20,00020,000Form 4
2026-09-01Piccina CintiaofficerOption exercise20,00060,000Form 4
2026-06-29Azelby RobertdirectorAward / grant47,50047,500Form 4
2026-06-29Bain LindadirectorAward / grant31,66731,667Form 4
2026-06-29Bain LindadirectorAward / grant47,50047,500Form 4
2026-06-29BUTITTA CYNTHIA MdirectorAward / grant31,66731,667Form 4
2026-06-29BUTITTA CYNTHIA MdirectorAward / grant47,50047,500Form 4
2026-06-29Iannone RobertdirectorAward / grant31,66731,667Form 4
2026-06-29Iannone RobertdirectorAward / grant47,50047,500Form 4
2026-06-29BONNEY MICHAEL WdirectorAward / grant31,66731,667Form 4
2026-06-29Leiderman ElisabethdirectorAward / grant47,50047,500Form 4
2026-06-29Richardson RyandirectorAward / grant31,66731,667Form 4
2026-06-29Richardson RyandirectorAward / grant47,50047,500Form 4
2026-06-29Rao Madduri RavindirectorAward / grant31,66731,667Form 4
2026-06-29Rao Madduri RavindirectorAward / grant47,50047,500Form 4
2026-06-29YOUNG WILLIAM DdirectorAward / grant31,66731,667Form 4
2026-06-29YOUNG WILLIAM DdirectorAward / grant47,50047,500Form 4
2026-06-29Leiderman ElisabethdirectorAward / grant31,66731,667Form 4
2026-06-29BONNEY MICHAEL WdirectorAward / grant47,50047,500Form 4
2026-06-29Azelby RobertdirectorAward / grant31,66731,667Form 4

Source: SEC Form 4 filings. Each row links to its original filing.

Across 2012–2021, stocks where a CEO, C-suite officer, or director had recently made an open-market common-stock purchase ran about +28 bp per month above the universe average (n=34,268 stock-weeks). A historical tendency, not a prediction.

Congressional disclosures

No congressional trades disclosed for this company.

Research tool, not investment advice — historical frequencies, not recommendations. A product of Marovel Technologies LLC. Full terms.